Rhythm Pharmaceuticals reported third-quarter 2025 net product revenue of $51.3 million and, more importantly, secured FDA priority review for a supplemental NDA of setmelanotide in acquired hypothalamic obesity, with a December 20, 2025, PDUFA date. U.S. sales rose 19% sequentially to $38.2 million, primarily driven by increased utilization for Bardet-Biedl syndrome, while ex-U.S. revenue declined amid early-access and ordering variability. The company also finalized a reimbursed price in France for BBS and POMC/LEPR deficiencies, recording a one-time $3.2 million charge. Cash, cash equivalents, and short-term investments totaled $416.1 million at quarter-end, supporting a guidance range of $295–$315 million in non-GAAP operating expenses for 2025.
The HO filing is the strategic hinge. If approved, setmelanotide moves from a tightly defined genetic rare-disease franchise into an acquired neuroendocrine condition that sits at the intersection of endocrinology, neuro-oncology, and post-surgical care. That expansion raises a central commercial question: can an MC4R agonist establish clinical and economic separation from the powerful gravitational pull of GLP-1-based care, given widespread off-label experimentation and payer tools designed to corral obesity drug budgets?
Timing and evidence work in tandem here. Rhythm is focusing its scientific narrative at ObesityWeek on data from the Phase 3 program on setmelanotide in HO patients previously or concurrently on GLP-1 therapy, as well as cardiometabolic outcomes. That’s a deliberate attempt to address sequencing and combination paradigms that payers and guideline bodies are already probing. The company also flagged a German observational study in BBS linking setmelanotide to improvements in MASLD and kidney function—signals that, while not label-defining, buttress a broader outcomes story that resonates with integrated payer models focusing on liver and renal risk reduction.
For Medical Affairs teams, HO represents a diagnostic and education challenge rather than a genetic testing exercise. Identification will depend on codified criteria, documentation of hypothalamic injury, and clear pathways across pediatric and adult endocrinology, neurosurgery, and oncology survivorship clinics. Real-world evidence will be pivotal to close the gap between efficacy and utilization, particularly to validate adherence and benefit in complex, comorbid populations. For HCPs, the practical questions will include positioning relative to GLP-1s, patient selection where hyperphagia is prominent, and potential additive benefits in those with hypothalamic MC4R pathway disruption.
Commercially, the quarter underscores the current center of gravity in the U.S., where specialty distribution, patient services, and prescriber familiarity can be scaled more predictably than ex-U.S. markets. The French price agreement highlights both opportunity and friction: converting early access into durable reimbursement, managing clawbacks, and planning for country-by-country variability. As EMA validates Rhythm’s Type II variation for HO, European market access will hinge on credible prevalence estimates, cost-offset modeling beyond weight loss, and alignment with evolving HTA expectations for metabolic and neuroendocrine disorders.
The pipeline cadence is designed to keep the story warm through 2026: preliminary Phase 2 data in Prader-Willi syndrome in the fourth quarter of 2025, Phase 3 readouts in genetically defined MC4R diseases and a Japanese HO cohort in the first quarter of 2026, and progress on a weekly MC4R agonist (RM-718) and a potential pivotal program for bivamelagon. With obesity therapeutics becoming a capital-intensive arms race, Rhythm is carving a defensible niche where mechanism matters as much as the magnitude of weight loss. The next test is not just regulatory. If the HO approval lands, will payers institutionalize setmelanotide as a first-line specialty option in defined hypothalamic injury, or require GLP-1 failure first—effectively relegating MC4R agonism to a rescue role and reshaping the franchise’s growth curve?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
